Entero Therapeutics Inc (ENTO)

Mar 24, 2025, 10:51 PM EDT - 9 days ago

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Feb 14, 2025, 4:00 PM EST - 6 weeks ago

Entero Therapeutics Appoints Richard Paolone as CEO

Feb 7, 2025, 3:22 PM EST - 7 weeks ago

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

Nov 15, 2024, 8:00 AM EST - 4 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

PULM

Nov 14, 2024, 6:50 PM EST - 4 months ago

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

Nov 13, 2024, 7:00 AM EST - 5 months ago

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Oct 8, 2024, 5:00 AM EDT - 6 months ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS ONCO VRNA

Aug 23, 2024, 5:00 PM EDT - 7 months ago

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Jul 31, 2024, 7:00 AM EDT - 8 months ago

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Jun 27, 2024, 6:00 AM EDT - 9 months ago

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

May 22, 2024, 7:00 AM EDT - 11 months ago

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

May 20, 2024, 7:00 AM EDT - 11 months ago

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference